- cafead   Apr 24, 2020 at 11:42: AM
via Affinivax, a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.
article source
article source